Home - Outlook Therapeutics

Loading...

LYTENAVA™ (bevacizumab-vikg) injection is now FDA-approved! Learn More

Outlook Therapeutics is focused on advancing innovative ophthalmic therapies for retinal diseases. With the FDA approval of LYTENAVA, the company continues that focus by bringing an important new treatment option to adults with neovascular (wet) age-related macular degeneration (nAMD).

ONS-5010: A uniquely positioned anti-VEGF therapy for wet AMD, DME and BRVO

HomeBarry Cantrell2026-07-24T19:02:24+00:00

Featured news

Outlook Therapeutics proudly introduces LYTENAVA, the first and only FDA-approved ophthalmic bevacizumab formulation for the treatment of nAMD (wet AMD).

Explore More
Outlook Therapeutics presents LYTENAVA (bevacizumab-vikg) Safety and Efficacy in Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration.

View Presentation
Recent press releases

July 24, 2026

Outlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD

Read the full release
June 16, 2026

Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg) as a Treatment for Wet AMD

Read the full release

© 2018-2026 Outlook Therapeutics, Inc.
This site is intended for a US audience only.
Privacy Notice | Disclaimer | Terms of Use | Cookie Notice

This website contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations, estimates, and projections, and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements. We undertake no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Readers are cautioned not to place undue reliance on these forward-looking statements.

Go to Top